Suzanne Randle
Associate Director, Oncology Targeted Discovery Safety AstraZeneca
Suzanne is an Associate Director in Oncology Safety, where she leads the early discovery in vitro bone marrow testing at AstraZeneca. A cell biologist by training she has extensive experience in vitro model development, with a focus on bone marrow toxicities of oncology therapeutics from small molecules to ADCs, through to combination assessments. She was awarded her PhD in 2012 from the University of Cambridge, with time spent at the Mayo Clinic Florida, Cambridge Institute for Medical Research and the Department of Pathology in Cambridge researching fundamental mechanisms of disease.
Seminars
Tuesday 24th February 2026
Exploring Development of an In Vitro Bone Marrow Strategy to Recapitulate & Support ADC Toxicity Assessment
11:00 am
- Delving into the development of a suite of bone marrow in vitro models to utilise in preclinical ADC haematotoxicity assessment
- Evaluating in vitro model capability to replicate clinical ADC toxicities and support drug development
- Understanding limitations of ADC in vitro models and exploring future directions to overcome them
